IN
INKT.US Mink Therapeutics Inc
- Market cap
- USD 47.9M
- P/E
- -
- P/B
- 11.33x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INKT.US undervalued?
Graham numberThe Graham number of Mink Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mink Therapeutics Inc fundamental analysis
No fundamental analysis for Mink Therapeutics Inc yet.
Mink Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mink Therapeutics Inc
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botens…
Full company profileMink Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mink Therapeutics Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 690K | 0.00 | 0.00 | 2.70B | 0.00 | 0.00 | 0.00 | 267K |
| Gross Profit | 690K | -55.1K | -78.0K | -122K | -205K | -215K | -182K | -3.61M |
| Operating Income | -22.3M | -10.8M | -18.6M | -30.9M | -22.9M | -10.7M | -12.5M | -11.6M |
| EBITDA | -22.2M | -13.7M | -27.7M | -27.9M | -22.3M | -10.6M | -12.3M | -11.2M |
| Net Income | -23.8M | -16.2M | -30.2M | -28.0M | -22.5M | -10.8M | -12.5M | -11.2M |
| EPS | -9.89 | -4.91 | -9.03 | -8.31 | -6.54 | -2.79 | -2.93 | -2.20 |
| Balance Sheet | ||||||||
| Total Assets | 1.31M | 4.56M | 40.2M | 21.5M | 4.55M | 5.72M | 14.2M | 8.24M |
| Total Liabilities | 37.6M | 58.4M | 16.5M | 21.9M | 22.6M | 25.3M | 28.5M | 24.5M |
| Shareholders' Equity | -36.3M | -53.9M | 23.8M | -401K | -18.1M | -19.6M | -14.2M | - |
| Cash & Short-term Investments | 299K | 2.69M | 38.9M | 19.6M | 3.37M | 4.58M | 13.4M | 7.47M |
| Total Debt | 26.8M | 43.8M | - | - | - | 4.92M | 5.18M | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -14.9M | -8.34M | -12.8M | -18.9M | -15.8M | -9.56M | -5.93M | -6.79B |
| Capital Expenditure | 426K | 95.2K | 249K | 250K | 73.6K | 4.00 | 0.00 | 0.00 |
| Free Cash Flow | -15.4M | -8.43M | -13.1M | -19.1M | -15.8M | -9.56M | -5.93M | -6.79B |
| Ratios | ||||||||
| ROE | - | - | -127.1% | - | - | - | - | - |
| ROA | -1,818.5% | -356.5% | -75.1% | -130.4% | -493.3% | -188.5% | -87.7% | -136.2% |
| Net Profit Margin | -3,451.5% | - | - | -1.0% | - | - | - | -4,211.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mink Therapeutics Inc dividends
Mink Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:10 on Jan 28, 2025.
Who owns Mink Therapeutics Inc
- Insiders 59.35%
- Institutions 4.08%
- Public & others 36.58%
- Shares outstanding 5.13M
- Free float 2.07M
Top funds holding INKT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 53.1K | 1.04% | 0.00% | Sep 2026 |
| DNB Fund Disrpt Opps A EUR Acc | 49.5K | 0.97% | -10.19% | Sep 2026 |
| Fidelity Extended Market Index | 9.91K | 0.19% | +46.72% | Sep 2026 |
| iShares Micro-Cap ETF | 6.12K | 0.12% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 2.89K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.88K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.53K | 0.03% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 445.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding INKT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 68.7K | 1.35% | +15.66% | Jun 2026 |
| DnB NOR Asset Management (Asia) | 55.1K | 1.08% | 0.00% | Jun 2026 |
| Longbow Finance SA | 16.7K | 0.33% | 0.00% | Sep 2026 |
| Geode Capital Management, LLC | 15.6K | 0.31% | -10.22% | Jun 2026 |
| Citadel Advisors Llc | 15.4K | 0.30% | 0.00% | Jun 2026 |
| BlackRock Inc | 13.4K | 0.26% | +115.73% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 8.29K | 0.16% | 0.00% | Jun 2026 |
| UBS Group AG | 4.89K | 0.10% | -67.87% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 2.00K | 0.04% | 0.00% | Jun 2026 |
| U.S. Bancorp | 2.00K | 0.04% | 0.00% | Jun 2026 |
| Paladin Partners, LLC | 1.00K | 0.02% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 500.00 | 0.01% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 422.00 | 0.01% | +170.51% | Jun 2026 |
| Covestor Ltd | 119.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 117.00 | 0.00% | +11,600.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 113.00 | 0.00% | +8.65% | Jun 2026 |
| Barclays PLC | 24.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 23.00 | 0.00% | 0.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 18.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 18.00 | 0.00% | +80.00% | Jun 2026 |
Mink Therapeutics Inc company profile
- Company name
- Mink Therapeutics Inc
- Ticker
- INKT.US
- Exchange
- USA Stocks
- Listed since
- Oct 15, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- 149 Fifth Avenue, New York, NY, United States, 10010
- Phone
- 212 994 8250
- Website
- minktherapeutics.com
About Mink Therapeutics Inc
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.
Mink Therapeutics Inc management
6- Dr. Garo H. Armen Ph.D.Executive Chairman · born 1953
- Dr. Jennifer S. Buell Ph.D.Co-Founder, President, CEO & Director · born 1975
- Ms. Melissa OrilallPrincipal Financial Officer · born 1989
- Mr. Austin CharettePrincipal Accounting Officer · born 1989
- Dr. Terese C. Hammond M.D.Head of Inflammatory & Pulmonary Diseases
- Dr. Marco PurbhooHead of Translational Medicine